SE0103476D0 - New use - Google Patents
New useInfo
- Publication number
- SE0103476D0 SE0103476D0 SE0103476A SE0103476A SE0103476D0 SE 0103476 D0 SE0103476 D0 SE 0103476D0 SE 0103476 A SE0103476 A SE 0103476A SE 0103476 A SE0103476 A SE 0103476A SE 0103476 D0 SE0103476 D0 SE 0103476D0
- Authority
- SE
- Sweden
- Prior art keywords
- new use
- substance
- pharmaceutical composition
- relates
- alcoholism
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 101710151321 Melanostatin Proteins 0.000 abstract 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 1
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 abstract 1
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103476A SE0103476D0 (sv) | 2001-10-18 | 2001-10-18 | New use |
| US10/492,785 US20050014742A1 (en) | 2001-10-18 | 2002-10-18 | Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism |
| PCT/SE2002/001902 WO2003032992A1 (en) | 2001-10-18 | 2002-10-18 | Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103476A SE0103476D0 (sv) | 2001-10-18 | 2001-10-18 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0103476D0 true SE0103476D0 (sv) | 2001-10-18 |
Family
ID=20285692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0103476A SE0103476D0 (sv) | 2001-10-18 | 2001-10-18 | New use |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20050014742A1 (sv) |
| SE (1) | SE0103476D0 (sv) |
| WO (1) | WO2003032992A1 (sv) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030754A1 (en) | 2003-09-24 | 2005-04-07 | Janssen Pharmaceutica, N.V. | Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| AU2006255097B2 (en) | 2005-06-06 | 2012-02-09 | Georgetown University | Compositions and methods for lipo modeling |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9500601D0 (en) * | 1995-01-12 | 1995-03-01 | Wellcome Found | Modified peptides |
| DE19816929A1 (de) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
-
2001
- 2001-10-18 SE SE0103476A patent/SE0103476D0/sv unknown
-
2002
- 2002-10-18 WO PCT/SE2002/001902 patent/WO2003032992A1/en not_active Application Discontinuation
- 2002-10-18 US US10/492,785 patent/US20050014742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050014742A1 (en) | 2005-01-20 |
| WO2003032992A1 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DE60204403D1 (de) | Feste orale Dosierungsform von Simethicon | |
| EA200700934A1 (ru) | Производные пиримидина и их применение в качестве модуляторов cb2 | |
| CR8824A (es) | Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| LTPA2016043I1 (lt) | 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| NO20034230D0 (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
| NO20042844L (no) | 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| IS6986A (is) | Lyfjasamsetning í vökvaformi | |
| ATE354362T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| SE9901077D0 (sv) | Novel use | |
| CL2003002293A1 (es) | Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. | |
| BR0213684A (pt) | Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas | |
| DE50305374D1 (de) | Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel | |
| DK1624869T3 (da) | Doseringsform indeholdende pantoprazol som aktiv bestanddel | |
| DE60134735D1 (de) | Neue neurokinin-antagonisten zum gebrauch als arzneimittel | |
| ATE409040T1 (de) | Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität | |
| SE0103476D0 (sv) | New use | |
| SE0102910D0 (sv) | New use | |
| SE0000303D0 (sv) | Novel compounds | |
| ATE409032T1 (de) | Orodispersible pharmazeutische zusammensetzung einer antithrombotischen verbindung |